1.
Sandoz M, Keusch G. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - an analysis of the RENAAL study. Swiss Med Wkly [Internet]. 2004 Aug. 7 [cited 2025 Feb. 18];134(3132):440-7. Available from: https://smw.ch/index.php/smw/article/view/399
